Abstracts

Ledipasvir/Sofosbuvir for 6 Weeks in HIV-Infected Patients With Acute HCV Infection

There is no currently approved treatment for acute HCV infection. Guidelines recommend 24 weeks of therapy with interferon (IFN) and ribavirin in HIV coinfected individuals who are diagnosed with acute HCV. Shorter duration therapy with all-oral agents may offer a better-tolerated more efficacious  alternative. Here we evaluated the safety, tolerability and efficacy of ledipasvir (LDV)/sofosbuvir…

HIV in Fishing Communities: Prevalence, Incidence, Risk Factors, and Interventions

As the world coalesces around achieving WHO’s 90-90-90 targets, initial steps are focused on finding and shutting down sources of new infections. We sought to describe the burden, risk factors and potential prevention interventions for HIV infections in fishing communities. This largely involves syntheses of published findings as well as findings from recent studies in the…

HIV and Migrants

Migrants have been long identified as one of the populations with highest vulnerability to HIV infection and its consequences.  Migrants encompass heterogeneous groups of persons with different migration drivers – economic, social, political, cultural and environmental – as well as with distinct risk-contexts for HIV infection. Some migrant groups have a disproportionate burden of HIV…

Global Epidemiology of HIV Infection in Adolescents

Global HIV surveillance estimates variably categorize adolescents (10-19 years) with children (<15 years), youth (15-24 years), and non-adults (<25 years).  At the end of 2013, there were 2.1 million adolescents living with HIV (ALHIV), 220,000 of whom had been newly infected that year.  In 2014, there were 3.9 million youth with HIV, of whom 2.8…

Pharmacokinetics, Safety, and Efficacy of Maraviroc in Pediatric Patients With R5 HIV

Maraviroc (MVC) is a CCR5 antagonist approved to treat adults infected with CCR5-tropic (R5) HIV-1. Study A4001031 was conducted to evaluate the pharmacokinetics (PK), safety and efficacy of MVC in treatment-experienced (TE) pediatric patients. This is an open-label, two-stage (stage 1: dose-finding; stage 2: safety/efficacy), age-stratified, non-comparative, multicenter study to evaluate the PK, safety and…